AccuContour
Physician Workstation with AI-Contouring for radiation therapy
Software · OtherCompany source
Company profile
About Xiamen Manteia Technology
Manteia Technologies is a technology-driven company specializing in vendor-independent radiation therapy software for cancer treatment. Founded in 2017 in Xiamen, China, the company originated from the Adaptive Research Group in the U.S., with a team of experienced physicians and medical physicists from clinical backgrounds. Manteia's comprehensive radiation oncology solution encompasses image-based treatment planning, quality assurance and quality control (QA/QC), and Adaptive Radiation Therapy (ART). Their product suite includes AccuContour for AI-powered contouring, AccuLearning as a deep learning training platform, Mozi TPS for next-generation treatment planning, and Monte Carlo-based QA solutions for patient QA and machine QC. The company's fully interoperable system integrates seamlessly into existing clinical workflows, enhancing treatment accuracy and adaptability. Manteia serves radiation oncology departments, medical physics teams, and cancer treatment centers globally, with recent deployments including Responsible Research Hospital in Italy. Their mission is to celebrate life with technologies by developing intelligent, adaptive, and precision-driven solutions that enhance cancer care and improve patient outcomes.
Company description Xiamen Manteia Technology official website
Primary marketSurgical AI & Robotics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Xiamen Manteia Technology?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer
- Oncology conditions requiring radiation therapy
Who it serves
- Cancer treatment centers
- Hospital radiotherapy departments
- Proton therapy centers
- Radiation oncology departments
Deployment & integration
On Premise · Other deployment with recorded integration context.
Geographic context
MarketsChina · International markets · Italy · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launch of Online Adaptive Radiotherapy (oART) at Responsible Research Hospital in Italy powered by Mozi TPS (2025). New official website launch featuring flagship products (April 2025). Italian media coverage describing deployment as 'Epochal Turning Point' and entry into Radiotherapy 4.0 era.
Partnerships
Recorded partners
- New York Proton Center
- Responsible Research Hospital (formerly Gemelli Molise), Italy
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
AccuLearning
Deep Learning Powered Local Training Platform for radiation oncology
Platform · On PremiseCompany source
Mozi TPS
Next Generation Treatment Planning System with AI and Adaptive Radiotherapy
Software · OtherCompany source
QA Solution
Monte Carlo Patient QA and Machine QC for radiation therapy
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
AccuContourK191928 · 510k · Feb 28, 2020
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Time savings
AccuContour saves hundreds of hours for planners in the contouring step
Workflow efficiency
Maintains high efficient workflow recognized by physicians
Treatment accuracy and adaptability
Enhanced through AI and Monte Carlo integration
Responsible Research Hospital (formerly Gemelli Molise)
Implementation of Online Adaptive Radiotherapy (oART) using software-driven approach without new hardware investment
Successfully launched Radiotherapy 4.0 capabilities powered by Mozi TPS, marking epochal turning point for the institution
New York Proton Center
AI-powered contouring to improve efficiency and quality in radiation therapy treatment planning workflow
Saves hundreds of hours for planners while maintaining high quality recognized by physicians
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Xiamen Manteia Technology
Recent articles published on Xiamen Manteia Technology's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Surgical AI & Robotics
Companies developing surgical technologies enhanced by AI, including robotic surgical systems, AI-powered surgical assistance and navigation tools, autonomous surgical robotics, and surgical data and analytics platforms. Covers both the performance of surgery and the analysis of surgical outcomes and OR efficiency.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.